ArticleCancer medicine2024

Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort study.

Aijun Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.